Leukemia: What Primary Care Physicians Need to Know

Joanne T. C. Gbenjo; Georgia L. M. McCrary; Sarah E. Wilson

JOANNE T. C. GBENJO, MD, GEORGIA L. M. MCCRARY, DO, AND SARAH E. WILSON, DO

Am Fam Physician. 2023;107(4):397-405

Patient information: See related handout on leukemia.

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Leukemia is caused by an abnormal proliferation of hematopoietic stem cells in the bone marrow. The four general subtypes are acute lymphoblastic, acute myelogenous, chronic lymphocytic, and chronic myelogenous. Acute lymphoblastic leukemia primarily occurs in children, whereas the other subtypes are more common in adults. Risk factors include certain chemical and ionizing radiation exposures and genetic disorders. Common symptoms include fever, fatigue, weight loss, joint pain, and easy bruising or bleeding. Diagnosis is confirmed with bone marrow biopsy or peripheral blood smear. Hematology-oncology referral is recommended in patients with suspected leukemia. Chemotherapy, radiation, targeted molecular therapy, monoclonal antibodies, or hematopoietic stem cell transplantation are common treatments. Complications from treatment include serious infections from immunosuppression, tumor lysis syndrome, cardiovascular events, and hepatotoxicity. Long-term sequelae in leukemia survivors include secondary malignancies, cardiovascular disease, and musculoskeletal and endocrine disorders. Five-year survival rates are highest in younger patients and those diagnosed with chronic myelogenous or chronic lymphocytic leukemia.

Leukemia is one of the most common malignancies in childhood, but it also often occurs in adults. It is caused by disruptions in the normal cell regulatory process that leads to uncontrolled proliferation of hematopoietic stem cells in bone marrow. From 2015 to 2019, the age-adjusted incidence of leukemia in the United States was 14.1 per 100,000 people per year.¹ In the past decade, the incidence of leukemia has been decreasing while survival rates have been increasing due to advancements in diagnosis and treatment.¹ The four general leukemia subtypes are acute lymphoblastic, acute myelogenous, chronic lymphocytic, and chronic myelogenous. Primary care physicians should be familiar with common presentations, initial diagnostic evaluation, principles of therapy, and long-term sequelae in survivors.

Clinical recommendation	Evidence rating	Comments
A peripheral blood smear should be obtained in patients with hyperleukocytosis (white blood cell count of more than 100,000 per μL [100 × 10⁹ per L]) and associated anemia, thrombocytopenia, thrombocytosis, hepatosplenomegaly, lymphadenopathy, or unexplained constitutional symptoms.^14,19,20,22	C	Expert opinion and consensus guideline in the absence of clinical trials
Asymptomatic, early-stage chronic lymphocytic leukemia (i.e., absence of anemia or thrombocytopenia and less than three areas of lymph node involvement) may be monitored without treatment.^4,19	C	Expert opinion and consensus guideline in the absence of clinical trials
Patients with leukemia who have neutropenic fever (i.e., less than 500 neutrophils per μL [0.5 × 10⁹ per L]) should be evaluated for an infectious source with prompt initiation of empiric broad-spectrum antibiotics.²⁷	C	Expert opinion and consensus guideline in the absence of clinical trials
Because of the potential for possible interactions between small-molecule inhibitors and commonly prescribed medications, a detailed medication review is recommended.²⁴	C	Expert opinion and consensus guideline in the absence of clinical trials
Patients who have survived leukemia should receive routine age- and sex-specific cancer screening and periodic complete blood count monitoring.^{16–19,24,27,30,32,33}	C	Expert opinion and consensus guideline in the absence of clinical trials

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia. Accessed June 1, 2022. https://seer.cancer.gov/statfacts/html/leuks.html

Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.

Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645-1666.

Strati P, Jain N, O'Brien S. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2018;93(5):651-664.

Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-2284.

Miglioretti DL, Johnson E, Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013;167(8):700-707.

Smith MT. Advances in understanding benzene health effects and susceptibility. Annu Rev Public Health. 2010;31:133-148.

Towle KM, Grespin ME, Monnot AD. Personal use of hair dyes and risk of leukemia: a systematic literature review and meta-analysis. Cancer Med. 2017;6(10):2471-2486.

Abar L, Sobiecki JG, Cariolou M, et al. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Ann Oncol. 2019;30(4):528-541.

Orgel E, et al. Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016;103(3):808-817.

Brix N, et al. Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children. Arch Dis Child. 2015;100(9):821-825.

Amrath Raj BK, Singh KA, Shah H. Orthopedic manifestation as the presenting symptom of acute lymphoblastic leukemia. J Orthop. 2020;22:326-330.

Clarke RT, Van den Bruel A, Bankhead C, et al. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Child. 2016;101(10):894-901.

Thompson PA, et al. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440-1454.

Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. Am Fam Physician. 2014;89(9):731-738.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute lymphoblastic leukemia. Accessed July 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. Accessed July 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myeloid leukemia. Accessed July 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic lymphocytic leukemia. Accessed July 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

de Haas V, Ismaila N, Advani A, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the College of American Pathologists and American Society of Hematology guideline [published correction appears in J Clin Oncol. 2019; 37(7): 612]. J Clin Oncol. 2019;37(3):239-253.

Coiffier B, Altman A, Pui C-H, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review [published correction appears in J Clin Oncol. 2010; 28(4): 708]. J Clin Oncol. 2008;26(16):2767-2778.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

Prasad V, Gale RP. What precisely is precision oncology—and will it work? The ASCO Post. January 25, 2017. Accessed June 1, 2022. https://www.ascopost.com/issues/january-25-2017/what-precisely-is-precision-oncology-and-will-it-work

Smith CEP, Prasad V. Targeted cancer therapies. Am Fam Physician. 2021;103(3):155-163.

Hochhaus A, Larson RA, Guilhot F, et al.; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-927.

Jones GL, Will A, Jackson GH, et al.; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661-671.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Accessed July 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf

Ferrara JLM, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000–2019. Accessed June 12, 2022. https://seer.cancer.gov/statistics-network/explorer/application.html

Baker KS, Syrjala KL. Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program. 2018;2018(1):146-153.

Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970–2015. JAMA. 2017;317(8):814-824.

Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. October 2018. Accessed July 1, 2022. http://survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf

Chow EJ, Anderson L, Baker KS, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group report. Biol Blood Marrow Transplant. 2016;22(5):782-795.

Continue Reading

More in AFP

More in PubMed

Subscribe

Issue Access

Article Only

Continue Reading

More in AFP

More in PubMed